Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  mitoxantrone hydrochloride
Find trials that include:  Any drugs shown
Results 1-20 of 20 for your search:
Start Over
Bortezomib and Sorafenib Tosylate in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: Under 30
Trial IDs: AAML1031, NCI-2011-02670, CDR0000701850, COG-AAML1031, NCT01371981
Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 30
Trial IDs: AALL1331, NCI-2014-00631, COG-AALL1331, NCT02101853
Tretinoin and Arsenic Trioxide in Treating Patients with Untreated Acute Promyelocytic Leukemia
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 12 to 21
Trial IDs: AAML1331, NCI-2014-02266, PAAML1331_A01PAMDREVW0, NCT02339740
A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2215-CL-0301, NCI-2015-00931, 2015-000140-42, NCT02421939
A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: T2009-003, NCI-2012-00563, NCT01483690
Decitabine Followed by Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 75
Trial IDs: 2652.00, NCI-2012-02224, 2652, NCT01729845
Study of Carfilzomib in Combination With Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and under
Trial IDs: CFZ008, NCI-2014-02601, 2014-001633-84, NCT02303821
Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GMI-1271-201, NCI-2015-01237, NCT02306291
Risk-Directed Therapy in Treating Young Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under
Trial IDs: ALLR18, NCI-2012-00587, NCT01700946
Microtransplantation in Treating Younger Patients with Refractory or Relapsed Hematological Malignancies
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: MITREL, NCI-2015-00691, NCT02433483
Brentuximab Vedotin, Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-040, NCI-2013-01114, NCT01830777
Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients with High-Risk Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-0111, NCI-2012-02028, 12-0111-AM002, 12-0111-CR003, NCT01839240
Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: HEMAML0024, NCI-2013-01349, 27313, NCT01904643
Ixazomib Citrate, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: CASE7913, NCI-2014-00371, MLN9708, X16014, X16014_MLN9708, NCT02070458
Selinexor and Chemotherapy in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 14089, NCI-2014-02229, NCT02299518
Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia
Phase: No phase specified
Type: Treatment
Age: 365 days and under
Trial IDs: CDR0000570260, NCI-2014-00665, CCLG-LK-2006-10, DCOG-INTERFANT-06, EUDRACT-2005-004599-19, NCT00550992
Donor Stem Cell Transplant in Treating Patients with High Risk Acute Myeloid Leukemia
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 9L-11-8, NCI-2013-00447, HS-12-00080, NCT01801046
Start Over